Ibogaine carries real cardiac risk — the medical screening and monitoring matter more than any other feature. Here's the country comparison.
Ibogaine is the most medically complex psychedelic medicine in clinical use. Unlike psilocybin, MDMA, LSD, DMT, or ayahuasca — none of which require continuous cardiac monitoring or pre-dose electrolyte loading — ibogaine prolongs the cardiac QT interval and has a documented mortality rate in unscreened settings. The medical infrastructure required for safe ibogaine administration is closer to outpatient anesthesia than to a wellness retreat, and the credible centers in this space operate accordingly.
The right mental model for an ibogaine retreat is not "psychedelic retreat with extra precautions." It is "small specialty clinic that uses a psychedelic medicine." The visionary phase of an ibogaine flood-dose is genuinely transformative for many patients, but the visionary phase is downstream of a successful medical workup. Without the workup, the experience and the safety footing both collapse.
This page is the cluster pillar for our ibogaine retreat coverage. The most consequential decision you can make about ibogaine treatment is choosing a clinic whose cardiac protocol is real. Everything below is structured around helping you recognize one.
Independent reviews of ibogaine-related deaths place mortality in unscreened or under-screened settings at roughly 1 in 300–400 treatments — a rate orders of magnitude higher than any other psychedelic. With proper cardiac screening, electrolyte loading, and continuous telemetry during the flood-dose, the rate drops by roughly an order of magnitude. The risk is medication-specific, not psychedelic-class general.
The mechanism is QT prolongation: ibogaine and its long-acting metabolite noribogaine block the hERG potassium channel, slowing the heart's electrical repolarization between beats. A prolonged QT can degenerate into torsades de pointes, a polymorphic ventricular tachycardia that can deteriorate into ventricular fibrillation and cardiac arrest. The screening protocol exists to identify and exclude the patients in whom QT prolongation will be dangerous, and to control the conditions (electrolytes, concurrent medications) under which it is administered.
Risk factors that compound the cardiac danger:
The single feature that separates a safe clinic from a dangerous one is whether the entire above list is operationalized — not just claimed on a website. A clinic that lacks any one element is gambling with patient lives. See the vetting checklist below for the operational test.
Ibogaine has different evidence bases for different indications. Honest assessment by indication:
Observational data from Mexican clinics (most notably MAPS-affiliated outcome studies and the Ambio/Stanford MISTIC collaboration) consistently show meaningful reductions in opioid use and craving following ibogaine treatment, with effects lasting weeks to months. Ibogaine appears to compress what would normally be multi-week opioid withdrawal into roughly 24 hours, and to interrupt drug-seeking circuits in a way that opens a 3–6 month window of reduced craving. No Phase 3 randomized controlled trial has been completed; the evidence base is observational. The Texas $50M IMPACT consortium and the Stanford trials are designed to close that gap.
The Stanford MISTIC study, published in Lancet Psychiatry, treated US Special Forces veterans with treatment-resistant TBI/PTSD using a magnesium-ibogaine protocol at the Ambio clinic in Tijuana. Pre/post measures of PTSD, depression, anxiety, and disability improved substantially and persisted at one month. VERITAS is a follow-on program. The early signal is striking but still single-arm; controlled trials are in progress.
Smaller observational studies and clinic outcome data suggest benefit for alcohol use disorder and treatment-resistant depression. Evidence is thinner than for opioid use disorder.
Some clinics treat stimulant use disorder. Published evidence is limited mostly to case series, with mixed outcomes.
Ibogaine's cardiac risk profile makes it a poor fit for non-indication recreational or psycho-spiritual use. The risk/benefit calculation only works when treating a serious indication that has resisted standard care.
Ibogaine is an indole alkaloid found in the root bark of Tabernanthe iboga, a shrub native to West Central Africa. The Bwiti tradition of Gabon has used iboga sacramentally for centuries; modern medical use began with Howard Lotsof's 1962 observation that ibogaine eliminated his opioid withdrawal symptoms.
Ibogaine's active metabolite is noribogaine (12β-hydroxyibogamine), formed via CYP2D6 demethylation. Noribogaine has a long half-life (24–60 hours, sometimes longer in CYP2D6 poor metabolizers) and is largely responsible for ibogaine's prolonged after-effects, including the persistent reduction in craving. Both ibogaine and noribogaine block the hERG potassium channel, which produces the QT prolongation that defines the cardiac risk profile.
Mechanism is multimodal: ibogaine acts at NMDA receptors (low affinity), kappa- and mu-opioid receptors (partial agonism at kappa), sigma-2 receptors, and serotonin transporters. The anti-addiction effect appears to be downstream of GDNF (glial cell line-derived neurotrophic factor) upregulation in the ventral tegmental area, which restores dopaminergic function disrupted by chronic opioid use. This is plausibly why a single dose can produce months of effect — the mechanism is neurotrophic rather than pharmacologic-blocker.
Practical pharmacokinetic implications:
Two protocol families dominate ibogaine treatment, and the choice matters for both efficacy and safety profile.
A single large oral dose of ibogaine hydrochloride — typically 12–20 mg/kg of patient body weight — given over a 24–36 hour session. This is the standard protocol for opioid use disorder. It produces the deep visionary phase (often described as a sustained "life-review" experience), the intense ataxia (you do not stand without help), and the strongest interruption of opioid withdrawal. Most published outcome data is for flood-dose protocols. It also produces the highest peak QT prolongation, which is why full cardiac monitoring and the screening protocol exist around it.
The total dose is divided into two or three smaller administrations several hours apart, sometimes over multiple days. Peak ibogaine concentrations are lower, and acute cardiac stress is reduced. The stacked protocol is sometimes used for patients at marginal screening tier, for psycho-spiritual rather than addiction work, or in programs where a single flood-dose feels too intense. Evidence base is thinner; outcome data for opioid use disorder specifically is less robust than for flood-dose.
Rather than purified ibogaine hydrochloride, some clinics — particularly in African Bwiti-influenced traditions — use total alkaloid extract from the iboga root bark, which contains ibogaine plus ibogamine, tabernanthine, and other alkaloids in the natural ratio. Cardiac risk profile is broadly similar; dosing precision is harder to achieve. Most medically rigorous programs use pharmaceutical-grade ibogaine HCl for that reason.
If you are evaluating a clinic, ask which protocol they use and why. A clinic that uses only flood-dose without flexibility — or only stacked without rigorous medical reasoning — is following a script rather than tailoring to the patient.
| Country | Legal status | Notes |
|---|---|---|
| Mexico | Not federally scheduled | Largest concentration of clinics globally (Cancún, Tijuana, Playa del Carmen). No ibogaine-specific regulatory framework — quality ranges from world-class (Beond, Ambio) to dangerous. See our Mexico guide. |
| Costa Rica | Permitted under physician supervision (regulated) | Only country with an explicit ibogaine medical-regulatory framework. Higher clinic floor; $8,000–$15,000 typical. See our Costa Rica guide and the law page. |
| New Zealand | Prescription only (non-approved medicine) | Permitted as a non-approved medicine under physician prescription per Medsafe guidance; small clinical scene. |
| South Africa | Schedule 6 — prescription required | Several clinics operate; physician-led, smaller scene than Mexico. |
| Brazil | Unscheduled | Several clinics; less established than Mexico. |
| Netherlands & Portugal | Unscheduled but unregulated | Small operator scenes; vetting critical. |
| Canada | Schedule III — research access only | Health Canada Section 56 exemptions used for research; no commercial clinics. |
| United States | Schedule I — research only | Stanford MISTIC/VERITAS, Texas $50M FDA-trial appropriation, Arizona $5M research program. No commercial access. |
| Tier | 5–10 day program | What you get |
|---|---|---|
| Budget / informal (Mexico) | $3,000–$5,500 | Often skips full cardiac protocol; lower physician hours; integration limited or absent. Highest mortality risk. |
| Mid (Mexico) | $5,500–$8,000 | Pre-arrival EKG, electrolyte loading, on-site physician during dosing, basic integration referral. |
| Full medical (Mexico) | $8,000–$12,000 | Full screening, continuous telemetry, anesthesiologist-or-equivalent during flood-dose, integration program with follow-up. Beond, Ambio, Crossroads tier. |
| Regulated (Costa Rica) | $8,000–$15,000 | Physician-licensed under CR framework, full screening, integration. Premium reflects regulatory-compliance cost — not optional in CR. |
| Research-affiliated / premium | $12,000–$25,000+ | Stanford MISTIC, MAPS-affiliated outcome tracking, longer aftercare, optional 5-MeO-DMT booster, structured follow-up at 30/90/180 days. |
Flights, ground transport, and travel medical insurance are extra. Most US health insurance does not cover ibogaine treatment because the substance is Schedule I in the US. Some clinics offer payment plans; verify in writing before committing.
The clinics with the best long-term outcomes share a feature that is invisible to most prospective patients: their integration and aftercare program is treated as part of the treatment, not an afterthought. Ibogaine appears to compress withdrawal and open a window — typically 3–6 months — in which cravings are reduced and the person has unusual access to insight about their use. Without active aftercare, that window closes and relapse rates climb sharply.
What good aftercare looks like:
Ibogaine remains Schedule I in the United States, but the research landscape changed substantially in 2024–2025. Key developments:
The realistic timeline to FDA approval is multi-year — Phase 2 data through 2026–2027, Phase 3 through 2028–2029, possible approval 2030 or later. For patients with urgent indications, traveling abroad remains the only access path through 2025–2026.
No. Ibogaine compresses withdrawal and resets craving for a window, but it is not a long-term replacement for buprenorphine or methadone. Many of the best long-term OUD outcomes involve ibogaine followed by re-initiation of medication-assisted treatment at a reduced dose, with eventual taper. Treating ibogaine as a one-shot cure is the single most common reason patients relapse.
Most patients describe a sustained, deeply internal "life-review" state during the peak phase (hours 4–10 of the flood-dose). The content is often centered on the trauma, loss, or use pattern driving the addiction; many people report a felt sense of being shown the consequences of their choices. Speech is difficult during the peak; ataxia means you do not stand without help. The introspective phase (hours 10–24) is quieter and processing-focused.
Most clinics require transition off methadone (a long-acting opioid that complicates the flood-dose mechanism) several weeks before treatment, often replaced by short-acting opioids that are then stopped 12–24 hours before dosing. Buprenorphine is similarly displaced. This transition is medically delicate and is one of the reasons the pre-arrival medical workup matters.
Almost certainly not for the ibogaine treatment itself (Schedule I in the US). Some travel medical insurance covers emergency hospital care during the trip — strongly recommended. A small number of HSAs allow distributions for unreimbursed medical care abroad; consult your tax advisor.
Some clinics offer a 5-MeO-DMT session 1–3 days after the ibogaine flood-dose as an integration tool. The short, intense 5-MeO-DMT experience is held to support and consolidate insights from the long ibogaine session. Evidence base is anecdotal rather than controlled; clinics offering it should treat it as optional.
Ask three specific questions in writing: (1) Will I receive a 12-lead EKG before dosing, and what is your exclusion criterion for QTc? (2) What is your magnesium and potassium loading protocol, and will my electrolytes be rechecked the morning of dosing? (3) Who is the on-site physician during my flood-dose, what is their cédula profesional or local license number, and what is your written hospital-transfer protocol? A clinic that answers all three crisply is doing it right. A clinic that deflects on any of them is not.
Get retreat & safety updates
When operators, regulations, or safety guidance for Ibogaine Retreats & Treatment Centers changes, we'll send you the update.
Suggest a tool, topic, or improvement that would make this site more useful.